Armen highlights the resilience of life sciences businesses, emphasizing their independence from economic cycles due to their innovative capabilities. He explains the typical borrower profile, which includes companies with FDA-approved products that are using loans to commercialize and fund clinical trials. This strategic approach allows them to balance growth while managing the risks associated with early-stage ventures.
